Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 6850
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
IMBdx, Inc. engages in the development of liquid biopsy tests for cancer diagnosis. It focuses on the following business areas: diagnosis and treatment of advanced cancer, early detection of recurrence after surgery, and early cancer diagnosis. Its products include AlphaLiquid, CancerDetect, and CancerFind. The company was founded by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E.
Data is available to registered users only
Buy
Sell